From November 21 until November 22, our Life Science team will be at ELRIG's High Content Imaging and Flow Cytometry in Drug Discovery 2023. This year, we are thrilled to showcase our groundbreaking Cell Voyager products, a series designed to revolutionize your laboratory's capabilities.
Our Cell Voyager range stands at the forefront of high-content analysis, offering unparalleled precision and flexibility. These systems are engineered to meet the diverse needs of modern drug discovery, providing robust and reliable data to accelerate your research.
At the Yokogawa booth, our team of experts will be available to discuss how our technologies can be integrated into your workflow to enhance efficiency and productivity. We will also be providing live demonstrations, giving you a firsthand look at the capabilities of our Cell Voyager products.
This event is an excellent opportunity to network with peers, learn about the latest trends and innovations in the field, and discover how Yokogawa's solutions can support your research objectives.
We look forward to seeing you at ELRIG 2023 at GSK in Stevenage and sharing with you the exciting advancements Yokogawa is bringing to the life sciences community.
Související průmyslová odvětví
Související produkty a řešení
-
High Content Analysis CellVoyager
Our high-content analysis (HCA) systems utilize powerful software to address a wide range of research applications from basic science to complex compound screening.
-
High Content Analysis System Solution
CellVoyager series can be easily connected to automation workflow.
-
Single-Cell Analysis Solutions Single Cellome™
We are developing cell handling technology for single-cell and live cells. SU10 provides selective, minimally damaging automated nano-point delivery. SS2000 provides automatically subcellular sampling based on confocal microscopy technology.
-
Spinning Disk Confocal CSU
Using our proprietary dual spinning disk design, Yokogawa’s confocal scanner units transform optical microscopes by enabling real-time live cell imaging.